Double PEGylation Significantly Improves Pharmacokinetic Properties of Irinotecan Containing Nanoparticles in a Zebrafish Model

Author(s): Uday Saxena*, Marina Rajadurai*, Surendar Basaveni, Swapna Yellanki, Raghavender Medishetti, Aarti Sevilimedu, Pushkar Kulkarni.

Journal Name: Current Nanomedicine
Formerly Recent Patents on Nanomedicine

Volume 9 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Plasma pharmacokinetic (PK) properties of oral or injectable drugs dictate whether the drug is clinically viable or not. Poor PK properties often result in termination of the development of the drug. Optimizing PK properties of drugs is a major challenge in the pharmaceutical industry. Ideally, sufficient circulating time of the drug in the plasma is required, so that it has adequate opportunity to reach the target tissue.

Methods: We have used irinotecan, a known drug with poor PK properties, as a prototype to apply our idea of improving PK in plasma by PEGylation. We compared the PK profile of free irinotecan, irinotecan packaged in nanoparticles (NPs) with single polyethylene glycol (PEG) layer and irinotecan packaged in NPs with double PEG layer. PK properties of these formulations were compared in a zebrafish model when given intraperitoneally.

Results: Dramatic differences in the PK properties of the three formulations were observed. The AUC, Cmax and T1/2 of irinotecan in each of these formulations differed from each other significantly. Approx. 4.5 - fold higher peak concentration (Cmax) and ~3 - fold higher exposure (AUC0-t) were observed for double PEGylated NPs as compared to free irinotecan and single PEGylated NPs.

Conclusion: In summary, our data suggest that double PEGylation of NPs could be a very effective way to improve PK properties of drugs such as irinotecan.

Keywords: Irinotecan, nanoparticles, nanoformulation, PEGylation, PK properties, Zebrafish, iron oxide.

[1]
Zhang X, Wang H, Ma Z, Wu B. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Expert Opin Drug Metab Toxicol 2014; 10: 1691-702.
[2]
Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-21.
[3]
Damodaran VB, Fee C. Protein PEGylation: An overview of chemistry and process considerations. Eur Pharm Rev 2010; 15: 18-26.
[4]
Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55: 1261-77.
[5]
Mishra P, Nayak B, Dey RK. PEGylation in anti-cancer therapy: An overview. Asian J Pharm Sci 2015; 11: 337-48.
[6]
Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives. Angew Chem Int Ed 2010; 49: 6288-308.
[7]
Barrow M, Taylor A, Murray P, Rosseinsky MJ, Adams DJ. Design considerations for the synthesis of polymer coated iron oxide nanoparticles for stem cell labelling and tracking using MRI. Chem Soc Rev 2015; 44: 6733-48.
[8]
Xu Q, Ensign LM, Boylan NJ, et al. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo. ACS Nano 2015; 9: 9217-27.
[9]
Liu T, Shi S, Liang C, et al. Iron oxide decorated MoS2 nanosheets with double PEGylation for chelator-free radiolabeling and multimodal imaging guided photothermal therapy. ACS Nano 2015; 9: 950-60.
[10]
Kulkarni P, Medishetti R, Nune N, et al. Correlation of pharmacokinetics and brain penetration data of adult zebrafish with higher mammals including humans. J Pharmacol Toxicol Methods 2017; 88: 147-52.
[11]
Kulkarni P, Rajadurai M, Sevilimedu A, et al. Magnetic nanoparticle formulation for targeted delivery of chemotherapeutic irinotecan to lungs. Drug Deliv Transl Res 2018; 1: 10.
[12]
Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 2011; 6: 715-28.
[13]
Laurent S, Forge D, Port M, et al. Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications. Chem Rev 2008; 108: 2064-110.
[14]
Boyer C, Whittaker MR, Bulmus V, Liu J, Davis TP. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications. NPG Asia Mater 2010; 2: 23-30.
[15]
Basuki JS, Jacquemin A, Esser L, Li Y, Boyer C, Davis TP. A block copolymer-stabilized co-precipitation approach to magnetic iron oxide nanoparticles for potential use as MRI contrast agents. Polym Chem 2014; 5: 2611-20.
[16]
Mohammadi MR, Malkovskiy AV, Jothimuthu P, et al. PEG/Dextran Double Layer Influences Fe Ion Release and Colloidal Stability of Iron Oxide Nanoparticles. Sci Rep 2018; 8: 4286.
[17]
Larsen EKU, Nielsen T, Wittenborn T, et al. Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. Nanoscale 2012; 4: 2352.
[18]
Nance EA, Woodworth GF, Sailor KA, et al. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med 2012; 4: 149ra119.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 2
Year: 2019
Page: [173 - 181]
Pages: 9
DOI: 10.2174/2468187308666180925143701
Price: $58

Article Metrics

PDF: 26
HTML: 3

Special-new-year-discount